Refer to the footnotes in the announcement. This has been well communicated by Acrux for quite a while now, and is pretty central to the current strategy (as it is for anyone in the generic drug business today).
"Because the Act also makes clear that filing an ANDA with a paragraph IV certification is an act of patent infringement, the law actually promotes litigation between private parties; the innovator is prompted to commence patent enforcement litigation against the generic infringer, and the generic company is incentivized to file a countersuit to have the patents listed in the Orange Book declared invalid."
ACR Price at posting:
12.5¢ Sentiment: None Disclosure: Held
